{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:58:08Z","timestamp":1793498288870,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA166051"],"award-info":[{"award-number":["R01CA166051"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA181029"],"award-info":[{"award-number":["R01CA181029"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP190029"],"award-info":[{"award-number":["RP190029"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cutaneous melanoma is the most malignant skin cancer. Biomarkers for stratifying patients at initial diagnosis and informing clinical decisions are highly sought after. Here we classified melanoma patients into three immune subtypes by single-sample gene-set enrichment analysis. We further identified a four-gene tumor immune-relevant (TIR) signature that was significantly associated with the overall survival of melanoma patients in The Cancer Genome Atlas cohort and in an independent validation cohort. Moreover, when applied to melanoma patients treated with the CTLA4 antibody, ipilimumab, the TIR signature could predict the response to ipilimumab and the survival. Notably, the predictive power of the TIR signature was higher than that of other biomarkers. The genes in this signature, <jats:italic>SEL1L3<\/jats:italic>, <jats:italic>HAPLN3<\/jats:italic>, <jats:italic>BST2<\/jats:italic>, and <jats:italic>IFITM1<\/jats:italic>, may be functionally involved in melanoma progression and immune response. These findings suggest that this four-gene signature has potential use in prognosis, risk assessment, and prediction of anti-CTLA4 response in melanoma patients.<\/jats:p>","DOI":"10.1038\/s42003-021-01911-x","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T11:03:43Z","timestamp":1616411023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma"],"prefix":"10.1038","volume":"4","author":[{"given":"Ying","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8721-0304","authenticated-orcid":false,"given":"Mei-Ju May","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-286X","authenticated-orcid":false,"given":"Han","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9965-989X","authenticated-orcid":false,"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"1911_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7\u201330 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"1911_CR2","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","volume":"1","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf, D. et al. Melanoma. Nat. Rev. Dis. Primers 1, 15003 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1911_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/phar.1895","volume":"37","author":"CS Lee","year":"2017","unstructured":"Lee, C. S., Thomas, C. M. & Ng, K. E. An overview of the changing landscape of treatment for advanced melanoma. Pharmacotherapy 37, 319\u2013333 (2017).","journal-title":"Pharmacotherapy"},{"key":"1911_CR4","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006\u20132017 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR5","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3389\/fimmu.2018.02909","volume":"9","author":"H Locy","year":"2018","unstructured":"Locy, H. et al. Immunomodulation of the tumor microenvironment: turn foe into friend. Front. Immunol. 9, 2909 (2018).","journal-title":"Front. Immunol."},{"key":"1911_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1028-7","volume":"17","author":"B Li","year":"2016","unstructured":"Li, B. et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 17, 174 (2016).","journal-title":"Genome Biol."},{"key":"1911_CR7","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/0008-5472.CAN-16-2490","volume":"77","author":"FS Varn","year":"2017","unstructured":"Varn, F. S., Wang, Y., Mullins, D. W., Fiering, S. & Cheng, C. Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment. Cancer Res. 77, 1271\u20131282 (2017).","journal-title":"Cancer Res."},{"key":"1911_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1586\/14737159.2014.928206","volume":"14","author":"C Camisaschi","year":"2014","unstructured":"Camisaschi, C., Vallacchi, V., Castelli, C., Rivoltini, L. & Rodolfo, M. Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment. Expert Rev. Mol. Diagn. 14, 643\u2013646 (2014).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"1911_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/pcmr.12371","volume":"28","author":"A Ladanyi","year":"2015","unstructured":"Ladanyi, A. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res. 28, 490\u2013500 (2015).","journal-title":"Pigment Cell Melanoma Res."},{"key":"1911_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/07357907.2017.1351984","volume":"35","author":"F Tas","year":"2017","unstructured":"Tas, F. & Erturk, K. Tumor infiltrating lymphocytes (TILs) may be only an independent predictor of nodal involvement but not for recurrence and survival in cutaneous melanoma patients. Cancer Invest. 35, 501\u2013505 (2017).","journal-title":"Cancer Invest."},{"key":"1911_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1911_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00262-018-2150-z","volume":"67","author":"F Finotello","year":"2018","unstructured":"Finotello, F. & Trajanoski, Z. Quantifying tumor-infiltrating immune cells from transcriptomics data. Cancer Immunol. Immunother. 67, 1031\u20131040 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"1911_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812\u2013830 e814 (2018).","journal-title":"Immunity"},{"key":"1911_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1158\/1541-7786.MCR-18-0173","volume":"17","author":"Y Zhao","year":"2019","unstructured":"Zhao, Y. et al. A leukocyte infiltration score defined by a gene signature predicts melanoma patient prognosis. Mol. Cancer Res. 17, 109\u2013119 (2019).","journal-title":"Mol. Cancer Res."},{"key":"1911_CR15","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"1911_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"1911_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","volume":"37","author":"Y He","year":"2018","unstructured":"He, Y., Jiang, Z., Chen, C. & Wang, X. Classification of triple-negative breast cancers based on Immunogenomic profiling. J. Exp. Clin. Cancer Res. 37, 327 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1911_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"1911_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"1911_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto, K. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581, 100\u2013105 (2020).","journal-title":"Nature"},{"key":"1911_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03730-x","volume":"9","author":"DJ McGrail","year":"2018","unstructured":"McGrail, D. J. et al. Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat. Commun. 9, 1317 (2018).","journal-title":"Nat. Commun."},{"key":"1911_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847\u2013856 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"1911_CR23","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","volume":"72","author":"G Erdag","year":"2012","unstructured":"Erdag, G. et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 72, 1070\u20131080 (2012).","journal-title":"Cancer Res."},{"key":"1911_CR24","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-16-0903","volume":"22","author":"RM Chabanon","year":"2016","unstructured":"Chabanon, R. M. et al. Mutational landscape and sensitivity to immune checkpoint blockers. Clin. Cancer Res. 22, 4309\u20134321 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1911_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"},{"key":"1911_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss, M. et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat. Commun. 8, 1738 (2017).","journal-title":"Nat. Commun."},{"key":"1911_CR27","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"1911_CR29","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45, D353\u2013D361 (2017).","journal-title":"Nucleic Acids Res."},{"key":"1911_CR30","doi-asserted-by":"publisher","first-page":"12297","DOI":"10.18632\/oncotarget.3655","volume":"6","author":"H Cirenajwis","year":"2015","unstructured":"Cirenajwis, H. et al. Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget 6, 12297\u201312309 (2015).","journal-title":"Oncotarget"},{"key":"1911_CR31","doi-asserted-by":"publisher","first-page":"e0176822","DOI":"10.1371\/journal.pone.0176822","volume":"12","author":"T Zhao","year":"2017","unstructured":"Zhao, T., Li, C., Wu, Y., Li, B. & Zhang, B. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysis. PLoS ONE 12, e0176822 (2017).","journal-title":"PLoS ONE"},{"key":"1911_CR32","doi-asserted-by":"publisher","first-page":"1593806","DOI":"10.1080\/2162402X.2019.1593806","volume":"8","author":"Q Fu","year":"2019","unstructured":"Fu, Q. et al. Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology 8, 1593806 (2019).","journal-title":"Oncoimmunology"},{"key":"1911_CR33","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"1911_CR34","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li, T. et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77, e108\u2013e110 (2017).","journal-title":"Cancer Res."},{"key":"1911_CR35","doi-asserted-by":"crossref","unstructured":"Coricovac, D. et al. Cutaneous melanoma-a long road from experimental models to clinical outcome: a review. Int. J. Mol. Sci. 19, 1566 (2018).","DOI":"10.3390\/ijms19061566"},{"key":"1911_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/bjc.2017.220","volume":"117","author":"TA Barnes","year":"2017","unstructured":"Barnes, T. A. & Amir, E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 117, 451\u2013460 (2017).","journal-title":"Br. J. Cancer"},{"key":"1911_CR37","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-17-3509","volume":"24","author":"D Tamborero","year":"2018","unstructured":"Tamborero, D. et al. A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations. Clin. Cancer Res. 24, 3717\u20133728 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1911_CR38","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949.e916 (2017).","journal-title":"Cell"},{"key":"1911_CR39","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"1911_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"1911_CR41","doi-asserted-by":"crossref","unstructured":"Pradhan, D. et al. Aberrant DNA methylation predicts melanoma-specific survival in patients with acral melanoma. Cancers (Basel) 11, 2031 (2019).","DOI":"10.3390\/cancers11122031"},{"key":"1911_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.vetimm.2011.06.020","volume":"143","author":"I Dietrich","year":"2011","unstructured":"Dietrich, I., Hosie, M. J. & Willett, B. J. The role of BST2\/tetherin in feline retrovirus infection. Vet. Immunol. Immunopathol. 143, 255\u2013264 (2011).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"1911_CR43","doi-asserted-by":"publisher","first-page":"11011","DOI":"10.1128\/JVI.01745-15","volume":"89","author":"AM Holmgren","year":"2015","unstructured":"Holmgren, A. M., Miller, K. D., Cavanaugh, S. E. & Rall, G. F. Bst2\/tetherin is induced in neurons by type I Interferon and viral infection but is dispensable for protection against neurotropic viral challenge. J. Virol. 89, 11011\u201311018 (2015).","journal-title":"J. Virol."},{"key":"1911_CR44","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1911_CR45","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"1911_CR46","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01911-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T19:19:01Z","timestamp":1670095141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01911-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1911"],"URL":"https:\/\/doi.org\/10.1038\/s42003-021-01911-x","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"24 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"383"}}